In 2013, lower health insurance rates saved consumers a total of $1 billion. States that enhanced their rate review programs will receive $25 million in rate review grant awards.
In 2013, lower health insurance rates saved consumers a total of $1 billion, according to a new report released by HHS Secretary Sylvia M. Burwell. She also announced 21 states would receive $25 million in rate review grant awards.
Through the Affordable Care Act (ACA)’s “rate review” provision and state efforts, consumers are already benefitting from lower-than-requested premium increases. Individuals saved $290 million in 2013 and small employers saved a total of $703 million. The ACA requires insurance companies publicly justify any rate increase of at least 10%.
“Before the Affordable Care Act, consumers regularly faced significant annual premium increases,” Burwell said in a statement. “In 2013 alone, we see that rate review programs saved consumers approximately $1 billion while providing them with the information they need to get the care they deserve.”
According to HHS’ report, implemented rate increases were smaller than what was originally requested in both the individual and small group markets. This is consistent with a trend in place since the rate review provision went into effect.
Rate review works in conjunction with the 80/20 rule, which requires insurers spend at least 80% of premium dollars on patient care and quality improvement activities. Insurers that spend an excessive amount on profits and “red tape” owe a refund to consumers, according to HHS. In 2012 and 2013, refunds from the 80/20 rule and lower than initially requested rates saved consumers more than $2.8 billion total.
States that enhance their rate review programs and bring greater transparency to the process are awarded Health Insurance Rate Review grants. This funding supports state efforts to review rate increases, educate consumers, help hold insurance companies accountable, and scrutinize medical pricing data.
The following 21 states are receiving awards: Arizona, Arkansas, California, Delaware, Hawaii, Indiana, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Nevada, New Hampshire, New Jersey, Oregon, Rhode Island, Utah, Vermont, Washington, and Wisconsin.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More